Suggested by Bloomberg, blessed by analysts, could an M&A match with a certain MS player be far off for blockbuster-hungry Sanofi?

All the signs are right.

Sanofi CEO Paul Hudson has an M&A war chest set aside from the sale of their Regeneron stock. A …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sug­gest­ed by Bloomberg, blessed by an­a­lysts, could an M&A match with a cer­tain MS play­er be far off for block­buster-hun­gry Sanofi?